Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Uremic toxins comprise a heterogeneous class of small molecules generated either directly by microbial fermentation of dietary substrates (such as amino acids and choline) or by host-microbial co-metabolism. The gut microbiome regulates the composition and quantity of these toxins, particularly in conditions like chronic kidney disease, where impaired renal clearance leads to systemic accumulation. Excess gut-derived uremic toxins drive multiple pathogenic processes, including inflammation, oxidative stress, cellular apoptosis, and disruption of tissue barriers, contributing to multiorgan dysfunction in affected individuals. Therapeutic strategies target both the removal of uremic toxins and the modulation of the gut microbiome to reduce toxin production.
Adsorption/sequestration of uremic toxins in the gut (AST-120) Modification of the microbiome to reduce production or increase degradation of toxins [probiotics/prebiotics/fecal transplant]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uremic toxin (microbiome-derived) (None in widespread use; sometimes abbreviated as "uremic toxins" or "UT").